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Background: The aim of this study was to evaluate the role of image heterogeneity analysis of standard
care magnetic resonance imaging (MRI) in patients with anal squamous cell carcinoma (ASCC) to predict
chemoradiotherapy (CRT) outcome. The ability to predict disease recurrence following CRT has the poten-
tial to inform personalized radiotherapy approaches currently being explored in novel clinical trials.
Methods: An IRB waiver was obtained for retrospective analysis of standard care MRIs from ASCC patients
presenting between 2010 and 2014. Whole tumor 3D volume-of-interest (VOI) was outlined on T2-
weighted (T2w) and diffusion weighted imaging (DWI) of the pre- and post-treatment scans.
Independent imaging features most predictive of disease recurrence were added to the baseline
clinico-pathological model and the predictive value of respective extended models was calculated using
net reclassification improvement (NRI) algorithm. Cross-validation analysis was carried out to determine
percentage error reduction with inclusion of imaging features to the baseline model for both endpoints.
Results: Forty patients who underwent 1.5 T pelvic MRI at baseline and following completion of CRT were
included. A combination of two baseline MR heterogeneity features (baseline T2w energy and DWI coef-
ficient of variation) was most predictive of disease recurrence resulting in significant NRI (p = 0 < 0.001).
This was confirmed in cross-validation analysis with 34.8% percentage error reduction for the primary
endpoint and 18.1% reduction for the secondary endpoint with addition of imaging variables to baseline
model.
Conclusion: MRI heterogeneity analysis offers complementary information, in addition to clinical staging,
in predicting outcome of CRT in anal SCC, warranting validation in larger datasets.
 2019 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 134 (2019) 119–126 This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Definitive chemoradiotherapy (CRT) with concomitant mito-
mycin C (MMC) and 5-fluorouracil (5-FU) forms the backbone of
anal squamous cell carcinoma (ASCC) management based on clin-
ical evidence from three pivotal phase III trials [1–3]. However, 25%
of patients will relapse following CRT, with 84% of recurrences
occurring within 2-years [4–6].
Currently, there is no reliable way to predict which patients will
experience disease recurrence following CRT. The ability to predict
response to CRT at baseline would be of significant clinical benefit
as it would allow the management to be individualized with per-
sonalization of RT dose. The baseline American Joint Committee
on Cancer (AJCC) tumor, node and metastasis (TNM) staging sys-
tem has undoubted prognostic value particularly for T3, nodepositive tumors [1,7,8]. Tumor involvement of the external sphinc-
ter and pre-treatment anal function score also have proven prog-
nostic value [9]. However, for node negative tumors and node
positive tumors that are 5 cm [8] there is greater variation in
reported outcomes and prognostic biomarkers are lacking.
The addition of clinical, biochemical and molecular markers to
clinical stage may improve predictive accuracy [10,11,12]. While
there is good supporting evidence that p16 negative patients are
at higher risk of failure following CRT [12], the fact that 90% of
human anal cancers are human papilloma virus (HPV)-driven, lim-
its its prognostic utility [13]. There have been preliminary sugges-
tions that factors such as tumor infiltrating lymphocytes may play
a role [13] and that genomic as well as cellular heterogeneity,
reflecting the presence of different malignant subclonal and stro-
mal cell populations, may affect clinical outcome [14]; however,
no particular clonal somatic mutations or biomarkers have been
reported to date to predict response to CRT in ACSS.
120 MRI heterogeneity analysis for outcome prediction in anal cancerIn terms of imaging, early post CRT assessment based on mag-
netic resonance imaging (MRI) morphology has limited value due
to confounding effects of treatment related changes [15], although
a tumor regression grading system (MRI-TRG) has shown some
promise in identifying patients who could benefit from early sal-
vage surgery for recurrence [16]. More recently there has been
interest in the potential of quantitative ‘phenotyping’ information
from medical images beyond volumetric and descriptive measures
[17] with the aim of improving patient stratification into distinct
phenotypic subgroups [18]. Still considered investigational, never-
theless such image analysis has shown promise in cancer manage-
ment, including cancer screening, diagnosis [19], treatment
response assessment [20,21] and more recently, in predicting
tumor molecular phenotype [18] and disease outcome [22].
We hypothesize that imaging features capture distinct pheno-
typic differences and may have prognostic value, supplementing
clinical and size/volume data in ASCC. Thus we aimed to assess
whether MRI heterogeneity features may predict disease recur-
rence or 2-year disease free survival (DFS) in ASCC undergoing CRT.Methods
Patient characteristics, treatment and follow-up
Institutional review board (IRB) waiver of informed consent was
obtained for this retrospective analysis of consecutive MRI data
obtained as part of the standard care pathway. Inclusion criteria
were histological diagnosis of anal SCC, completion of a course of
CRT with curative intent and availability of baseline MRI and a
follow-up MRI performed within 3–6 months of treatment. Cases
were recruited from two tertiary care institutions between 2010
and 2014. Exclusion criteria were the absence of DWI MRI
sequences, deviations from a standard MRI protocol, poor image
quality and absence of visible tumor (Fig. 1 suppl.).
The clinical variables considered for the purpose of multivariate
analysis included patient age at diagnosis, patient gender, binary
tumour size (<5cm vs 5 cm), N stage (N0/N1/N2/N3) and radio-
logical response (complete response (CR) vs no CR).
Radiotherapy was delivered to a mean dose of 50.86 Gy (range
50.4–54 Gy) using a linear accelerator (Elekta, Crawley or Varian,
Palo Alto) applying a 3-D conformal or intensity-modulated tech-
nique. Concomitant chemotherapy consisted of mitomycin C
(MMC) 12 mg/m2 day 1 with either 5-fluorouracil 1000 mg/
m2/day (continuous venous infusion) days 1–4 and 29–32 or cape-
citabine (825 mg/m2 twice a day on radiation days). Following
completion of CRT, patients were assessed at 8–10 weeks, every
3 months for the first two years and every 6 months afterwards.
Re-staging MRI was carried out at 3–6 months.Table 1
T2-weighted and diffusion-weighted MRI acquisition parameters utilized.
Sequence Acquisition parameters
(Center 1)
Acquisition
parameters
(Center 2)
T2 axial TSE TR/TE: 5010/137 ms; TR/TE: 5290/97 ms;
Tumor Flip angle 137 NSA 4;
ST 3 mm
FoV 220*220 mm
Flip angle 150 NSA 2;
ST 3 mm
FoV 200*200 mm
Diffusion axial SS-EPI TR/TE: 3000/65 ms; TR/TE: 3100/77 ms;
Pelvis Flip angle 90; NSA 4 Flip angle 90; NSA 4Clinical endpoints
The primary endpoint of this study was disease recurrence,
either locoregional (defined as biopsy-confirmed evidence of
non-complete response at restaging or locoregional tumour detec-
tion during follow-up after initial response) or metastatic (defined
as occurrence of distant metastasis during CRT, at re-staging, or
during follow-up). Patients who were alive and free of recurrences
or died without recurrence were censored for these endpoints. All
time-to-event end points were measured from completion of CRT.
Disease-free survival (DFS) was defined from completion of CRT to
the day of locoregional failure or distant recurrence.b = 0, 100, 500, 800,
(1100) s/mm2
ST 6 mm
Fov 260*260 mm
ST 6 mm
Fov 250*250 mm
TSE, turbo spin echo; TR, repetition time; TE, echo time; NSA, number of signals
averaged; ST, slice thickness; FoV, field of view; SS-EPI, single-shot echo planar
imaging.MRI acquisition and imaging response assessment
Pelvic MRI scans were performed at baseline and on completion
of CRT. Patients were scanned in the supine position on one ofthree 1.5 T MRI scanners (MAGNETOM Avanto or Aera, Siemens
Healthcare, Erlangen, Germany) using a pelvic phased array coil.
The standard MRI acquisition protocol included pelvic T2-
weighted (T2w) axial, T2w sagittal, T1-weighted axial and DWI
axial sequences (b = 0, 100, 500, 800 s/mm2); additional high-
resolution T2w sequences were undertaken parallel and perpen-
dicular to the anal canal. The protocols in the two centres albeit
similar, were not standardised for the purpose of this study;
respective acquisition details from participating centres have been
summarized in Table 1. Patients did not require any additional
preparation prior to the examination.
Axial-oblique T2w and the b800-value DWI images, as well as
vendor-produced apparent diffusion coefficient (ADC0–800) maps,
were downloaded from the PACS system onto a standalone work
station for further analysis.
Scans were analyzed by two independent readers (a clinical
oncologist and radiologist, with 2 and 10 years’ MRI experience,
respectively) in consensus, blinded to clinical data. Tumor maxi-
mum size, volume, extent and TNM stage were recorded. Response
to CRT was evaluated in relation to the tumor and nodal stage and
in accordance with Response Evaluation Criteria in Solid Tumors
(RECIST 1.1) and for the purpose of this study coded in a binary for-
mat (complete response versus incomplete/no response).Heterogeneity feature extraction and selection
Feature extraction and analysis workflow is outlined on Fig. 1.
The tumors were manually delineated on all slices of axial T2w
and on ADC parametric maps generating 4 separate whole tumor
3D volumes-of-interest (VOI) per case (baseline T2w, baseline
DWI, post-CRT T2w and post-CRT DWI). In cases where no residual
tumour was present on post-CRT MRI, the corresponding anatom-
ical region with any residual tumor or therapy related changes was
outlined, confined to the area of visible mucosal abnormality.
Seventy-eight statistical and fractal heterogeneity parameters
were derived per VOI using in-house developed software imple-
mented in Matlab (Matlab 2013, Mathworks, Natick, MA, USA)
[23]. Highly correlated variables (r > 0.9) and those exhibiting lin-
ear dependencies were removed resulting in ten first-, second-
order and fractal features per sequence per timepoint (Table 2).
Conventional tumor volume (cm3) was included in the analysis
alongside heterogeneity variables.Statistical analysis
Statistical analysis was conducted using R (version 3.5.0) Inde-
pendent heterogeneity features and conventional ROI volume from
baseline and follow-up scans were entered individually into uni-
variate logistic regression. The primary outcome was recurrence
(binary measure) and the secondary outcome was 2-year DFS.
Fig 1. Analysis workflow. Multi-slice regions of interest (ROI) were drawn around the tumor on high resolution T2w images as well as on Apparent Diffusion Coefficient (ADC)
parametric maps with reference to high b value diffusion weighted images (DWI), generating a 3D whole tumor volume. From this volume, first-, second- and high-order
statistical and fractal parameters were derived using in-house software. Both illustrated cases are of T4 anal canal tumors (Case 1 – Partial response post CRT, delayed
recurrence; Case 2 – Partial response post CRT, subsequently CR and no recurrence at last follow-up).
K. Owczarczyk et al. / Radiotherapy and Oncology 134 (2019) 119–126 121The Benjamini-Hochberg multiple testing correction procedure
was used to control the adjusted false discovery rate (FDR). Nom-
inal and FDR-adjusted p-values and 95% confidence intervals are
reported.
We used random forest approach [24], and its R package ran-
domForest (version 4.6–14) implementation, to select variables
with a highest discriminatory value (20% increase in the predic-
tion mean square error after variable permutation, %IncMSE) in
predicting primary and secondary outcome.
C-statistic (a goodness-of-fit measure similar to the receiver
operating characteristic area under the curve (AUC) as previously
reported [17]) was calculated for 1) baseline model = multivariate
clinical model including the following clinical variables (age, gen-
der, T stage, N stage); 2) extended model = clinical model with
the addition of top performing imaging features. As this was an
exploratory analysis intended to generate hypotheses that could
be tested in future cohorts, variables were selected for inclusion
in multivariate models based on a FDR-adjusted type I error rate
of 20% (adjusted P < 0.2).
In addition, we used a net reclassification improvement (NRI) –
a criterion designed to quantify improvement in model perfor-
mance as a result of adding a new marker [25,26] – to assess the
impact of extending the baseline clinico-pathological model by
imaging features. The NRI calculation procedure is implemented
in the R package nricens (version 1.6).
The candidate extended models were built by extending the
baseline model by each of the most important variables from the
random forest model (number of trees 1e5) as well as by their
two-element combinations with respect to the primary and sec-
ondary endpoints. Each model was cross-validated (leave-one-
out) using the R package boot (version 1.3–20). Outcome for each
model was reported as percentage average mean squared error
reduction from the baseline model for each of the endpoints with
baseline cross validation errors listed in the titles.Results
Patient and treatment characteristics
40 consecutive patients were included in the analysis (25
female, 15 male). Median age at diagnosis was 60.5 (range
37–83). The majority of cases were T2 (17/40, 45%) and T3
(14/40, 37%) tumors and there was an even distribution of N0
(13/40, 32.5%), N1 (12/40, 30%) and N2+ (15/40, 37.5%) disease.
Radiotherapy was delivered to a dose of 50.4 Gy in 28# in 34/40
(85%) cases and to a dose of 54 Gy in 30# in 5/40 (12%) cases over
a median of 37 days (RT details were not available for one subject).
Patients received fluoropyrimidine-based chemotherapy, either as
monotherapy or in combination with a single dose of MMC in
21/40 (53%) cases and in combination with cisplatin in 2/40 (5%)
cases.Clinical follow up
Median follow-up was 34.5 months (range 2–102 months) and
median time to recurrence was 25 months (2–102 months). During
the course of follow-up 11 patients experienced disease recurrence
(28%); 4 patients recurred locally, 5 patients recurred with both
local and metastatic disease and 2 recurred with metastatic disease
only (cervical lymph node and liver metastases, respectively). 4
patients underwent early salvage abdomino-perineal excision of
rectum (APER). 1 year, 2 year- and 3 year-disease free survival
(DFS) rate was 90%, 83% and 80%, respectively.Imaging response assessment
Post therapy MRI was performed at a median of 15 weeks
(range 5–19 weeks) from the start of radiotherapy with 90% of
scans performed within 12 weeks of completion of treatment.
Table 2
Summary description and relevant formulae for the independent first, second and fractal features analyzed.
Parameter Description Formula
First order: histogram statistics provide an indication of central tendency (coefficient of variation) and variability (kurtosis, energy and entropy)
Coefficient of Variation
(CoV)
Indicates how large the standard deviation is in relation
to the mean
r
l
Kurtosis Describes the ‘‘peak” of a distribution. Kurtosis >3:
sharper peak than a normal distribution Kurtosis <3:
flatter peak than a normal distribution Kurtosis = 3:
normal distribution
n
n1ð Þ n2ð Þ n3ð Þ
P
x;yð Þ2R a x;yð Þa½ 
4
sd að Þ½ 4  3
n1ð Þ2
n2ð Þ n3ð Þ
where n = the total number of voxels in the region-on-
interest, R within the image a(x,y); sd = standard
deviation; a¯ is the mean value within R
Energy Measures voxel signal distribution. High energy is noted
in homogeneous voxels
Pimax
i¼1 ½p ið Þ2
where i is the voxel value (between i = 1 to imax in the
region of interest and p(i) the probability of the
occurrence of that voxel value
Entropy Measures voxel randomness. Low entropy is noted in
homogeneous voxels
Pimax
i¼1 ½pðiÞln½pðiÞ
where i is the voxel value (between i = 1 to imax in the
region of interest and p(i) the probability of the
occurrence of that voxel value
Second order: Gray Level Co-occurrence matrix (GLCM) statistics are computed after the original texture image D is re-quantized into an image G with reduced
number of gray level, Ng by scanning the intensity of each voxel and its neighbour, defined by displacement d and angle h. A displacement, d could take a value of
1,2,3,. . .n whereas an angle, h is limited 0, 45, 90 and 135. The GLCM p i; jjd; hð Þ is a second order joint probability density function of gray level pairs in the image
for each element in the co-occurrence matrix by dividing each element with Ng. Finally, scalar secondary features are extracted from this co-occurrence matrix
GLCM: Correlation Measures gray level intensity linear dependence
between the voxels (i,j) at the specified positions relative
to each other
P
i
P
j ijð Þpði; jÞ
where i is the voxel value (between i = 1 to imax in the
region of interest; j is the voxel value (between j = 1 to
jmax in the region of interest; and p(i,j) the probability of
the occurrence of that voxel value i relative to j
GLCM: Cluster
prominence
Measures asymmetry. A low cluster prominence value
indicates small variations in gray-scale
P
i
P
jðiþ j lx  lyÞ4pði; jÞ
where i is the voxel value (between i = 1 to imax in the
region of interest; j is the voxel value (between j = 1 to
jmax in the region of interest; p(i,j) is the probability of
the occurrence of that voxel value i relative to j; mx is the
mean of px and my is the mean of py
Fractal features describe self-similar fractal shapes
Mean fractal
dimension
Measures the texture of a fractal, a self similar pattern. A
higher fractal dimension corresponds to greater
roughness
D

¼
PN
i¼1Di
N
where N is the number of slices and Diis the fractal
dimension for the ith slice
Standard deviation Measures the standard deviation of a fractal computed
by a differential box counting algorithm r ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPN
i¼1D
2
i =N 
PN
i¼1Di
N
 2s
where N is the number of slices and Diis the fractal
dimension for the ith slice
Lacunarity Measures the amount of ‘‘gaps” in the image/object. If a
fractal has large ‘‘gaps”, it has high lacunarity
PN
i¼1D
2
i =N
 
PN
i¼1Di
N
 2" # 1
where N is the number of slices and Diis the fractal
dimension for the ith slice
Hurst component Measures the density of the image/object i.e. how much
the image/object occupies the space that contains it. A
small value corresponds to coarse texture
H ¼ 3 D

where D

is the mean fractal dimension
122 MRI heterogeneity analysis for outcome prediction in anal cancer31/40 (73%) patients achieved a radiological complete response
(CR) on both T2-w and DWI. Radiological CR at this time point from
the start of CRT did not predict outcome (CR rate: 7/11 (64%) and
24/29 (83%), p = 0.2 in patients who subsequently recurred versus
patients who did not recur).Association between MR image heterogeneity and disease recurrence
The imaging features most strongly associated with disease
recurrence in univariate analysis were T2w energy and DWI coef-
ficient of variation (CoV) from baseline MRI scans (Table 1 suppl).
Patients who developed disease recurrence post CRT demonstrated
higher baseline T2w energy and higher DWI CoV. In comparison,
there was no statistically significant difference in either baseline
tumor or post-treatment residual volume in patients who experi-
enced recurrence versus those that did not, although the post-
treatment volume may have been over-represented as it included
radiotherapy- induced mucosal change and fibrosis (p = 0.35 and
p = 0.06, respectively).Predictive accuracy of the baseline clinic-pathological multi-
variate logistic regression model for disease recurrence including
age, gender, T stage (dichotomised) and N stage was numerically
increased with the addition of these two key imaging characteris-
tics (AUC = 0.71 for baseline vs AUC = 0.83 for extended model;
p = 0.25 for comparison), and baseline T2w energy remained asso-
ciated with disease recurrence after adjusting for clinical charac-
teristics (Fig. 2a; Table 3a).
We applied NRI analysis to the baseline and extended model
(including T2w energy and DWI CoV). Resulting NRI = 1.29 statistic
value indicates a significant (p-value <0.001) net reclassification
improvement by the addition of the 2 imaging variables to the
baseline model.Association between MR image heterogeneity and disease free survival
In the univariate analysis, the imaging features associated with
2-year DFS are listed in Table 2 suppl. When T2w energy and DWI
CoV were included in the multivariate regression model for 2-year
Fig 2. Receiver operator curves (ROC) for prediction of recurrence (a) and disease free survival (b) comparing model using clinical variables alone with model using clinical
and imaging variables as described in text.
Table 3
Results of the cross-validation analysis for extended models based on most predictive imaging variables. Error from each model cross-validation was reported together with its
percentage change from the baseline model one for each of the endpoints.
Model Primary endpoint (Disease
recurrence)
Secondary endpoint (2y-DFS)
CV error CV error change (%)
from the Baseline Model
CV error CV error change (%)
from the Baseline Model
Baseline Model 0.240 0.0 0.174 0.0
Baseline model extensions:
Baseline T2w Energy, Baseline T2w Entropy 0.186 22.8 0.142 18.3
Baseline T2w Energy, Baseline T2w GLCM: Cluster Prominence 0.181 24.5 0.148 14.9
Baseline T2w Energy, Post CRT T2w GLRL: Low Gray-Level Run Emphasis 0.201 16.2 0.168 3.2
Baseline T2w Energy, Post CRT T2w GLRL: Run Percentage 0.203 15.6 0.166 4.6
Baseline T2w Energy, Baseline DWI Coefficient of Variation 0.157 34.8 0.142 18.1
Baseline T2w Energy, Baseline DWI Standard Variation 0.183 23.7 0.217 24.7
Baseline T2w Entropy, Baseline T2w GLCM: Cluster Prominence 0.196 18.4 0.155 10.6
Baseline T2w Entropy, Post CRT T2w GLRL: Low Gray-Level Run Emphasis 0.221 8.2 0.173 0.2
Baseline T2w Entropy, Post CRT T2w GLRL: Run Percentage 0.222 7.8 0.172 1.3
Baseline T2w Entropy, Baseline DWI Coefficient of Variation 0.170 29.1 0.150 13.9
Baseline T2w Entropy, Baseline DWI Standard Variation 0.196 18.4 0.208 19.4
Baseline T2w GLCM: Cluster Prominence, Post CRT T2w GLRL: Low Gray-Level Run Emphasis 0.203 15.3 0.204 17.1
Baseline T2w GLCM: Cluster Prominence, Post CRT T2w GLRL: Run Percentage 0.205 14.6 0.208 19.8
Baseline T2w GLCM: Cluster Prominence, Baseline DWI Coefficient of Variation 0.171 28.7 0.173 0.3
Baseline T2w GLCM: Cluster Prominence, Baseline DWI Standard Variation 0.162 32.7 0.167 3.8
Post CRT T2w GLRL: Low Gray-Level Run Emphasis, Post CRT T2w GLRL: Run Percentage 0.257 6.8 0.208 19.7
Post CRT T2w GLRL: Low Gray-Level Run Emphasis, Baseline DWI Coefficient of Variation 0.178 25.7 0.151 13.0
Post CRT T2w GLRL: Low Gray-Level Run Emphasis, Baseline DWI Standard Variation 0.199 17.3 0.163 6.5
Post CRT T2w GLRL: Run Percentage, Baseline DWI Coefficient of Variation 0.179 25.3 0.152 12.8
Post CRT T2w GLRL: Run Percentage, Baseline DWI Standard Variation 0.200 16.6 0.163 6.3
Baseline DWI Coefficient of Variation, Baseline DWI Standard Variation 0.189 21.5 0.168 3.1
Baseline T2w Energy 0.188 21.7 0.121 30.3
Baseline T2w Entropy 0.203 15.4 0.134 22.6
Baseline T2w GLCM: Cluster Prominence 0.228 5.0 0.177 2.0
Post CRT T2w GLRL: Low Gray-Level Run Emphasis 0.247 3.0 0.198 14.1
Post CRT T2w GLRL: Run Percentage 0.248 3.3 0.201 15.4
Baseline DWI Coefficient of Variation 0.178 26.0 0.142 18.2
Baseline DWI Standard Variation 0.195 18.8 0.140 19.3
K. Owczarczyk et al. / Radiotherapy and Oncology 134 (2019) 119–126 123DFS based on clinical characteristics only, predictive accuracy was
improved from AUC 0.71 to AUC 0.95 (p = 0.09 for comparison)
(Fig. 2b; Table 3b).Model cross-validation for disease recurrence and 2y-DFS
The following variables were selected from the random forest
model which fulfilled the importance criterion: (Baseline T2wEnergy, Baseline T2w Entropy, Baseline T2w GLCM: Cluster Promi-
nence, Post CRT T2w GLRL: Low Gray-Level Run Emphasis, Post CRT
T2w GLRL: Run Percentage, baseline DWI Coefficient of Variation,
baseline DWI Standard Deviation). These variables, as well as all
their two-element combinations, were taken forward to be
included in the extended model (n = 7 + 21 models considered) as
compared to the baseline clinic-pathological model for both the
primary and secondary endpoints. For the primary endpoint the
Fig 3. Percentage change in cross-validation error from the baseline model for prediction of disease recurrence (a) and disease free survival (b).
124 MRI heterogeneity analysis for outcome prediction in anal cancermodel extended with T2w energy and DWI CoV resulted in the
greatest error reduction (34.8%) as compared to the baseline model
baseline (CV error = 0.24) (Fig. 3a, suppl Table 3).
For the secondary endpoint the model extended with T2w
Energy resulted in the greatest error reduction (30.3%) from base-
line (CV error = 0.174) whereas the combined model (T2w energy
and DWI CoV) provided reduction by 18.1% (Fig. 3b, suppl Table 3).
Discussion
In this exploratory analysis of imaging heterogeneity features
derived from standard care MRI acquired at baseline and following
CRT in patients with anal cancer, we identified two imaging fea-
tures, namely baseline T2w energy and DWI CoV, which appeared
to be predictive of CRT outcome, independent of clinical character-
istics alone. The addition of these two imaging features to multi-
variate logistic regression models based on clinical characteristics
including age, gender, T and N stage yielded numeric increases in
the predictive accuracy for both, disease recurrence as well as
2 year-DFS, when using both, conventional C-statistic as well as
recently described NRI algorithm.
The extended model (incorporating T2w energy and DWI CoV)
demonstrated 34.8% error reduction beyond baseline clinical
model in terms of disease recurrence prediction and 18.1% error
reduction in terms of 2y-DFS post CRT in an independent cross val-
idation analysis meriting its replication in a larger external valida-
tion cohort.
As we await the results of a prospective multi-center Australian
trial with the aim of determining whether the addition of func-
tional MRI sequences to morphological data has the potential to
predict later disease recurrence [27], to our knowledge, our study
is the first to explore the potential of functional MRI (including
DWI) heterogeneity analysis to predict clinical outcome following
CRT in anal cancer.
An imaging ‘‘radiomics” approach, extracting a large number of
quantitative texture features from diagnostic images, has the
potential to derive more in-depth characterization of the tumor,
helping to stratify patients into distinct phenotypic subgroups
[18] with the added advantage of being non-invasive and poten-
tially unaffected by sampling bias [11].
To our knowledge, only one previous study investigated the
association between baseline MR imaging heterogeneity featuresand outcome in patients with ASCC undergoing CRT [28]. The
authors identified two baseline imaging factors, extracted from
baseline T2w sequences, predictive of tumour related event occur-
rence, highlighting the potential usefulness of MR texture analysis
as a predictive factor of outcome for ASSC. The potential advantage
of our study is the larger sample size as well as functional (DWI)
sequences in the analysis.
Our results highlight the complementary nature of anatomical
and functional MR assessment in ASCC. This has also been appreci-
ated in other tumour types, in particular gliomas, where predictive
models combining radiomic features from multiple sequences (T1
and ADC) had higher diagnostic accuracy in discriminating low
grade from high grade gliomas than models based on features
extracted from a single sequence possibly due to the complexity
of the microenvironment in tumors [29]. In other studies, radiomic
‘‘signatures” employing heterogeneity analysis of multiple
sequences have been shown to correlate with molecular signa-
tures, such as multigene assays in breast cancer [30]
First-order energy is a measure of the overall uniformity
(homogeneity) of voxel gray levels while first-order coefficient of
variation is a measure of intensity variability (heterogeneity)
within an image. We therefore hypothesise that the higher base-
line anatomical uniformity combined with higher variation in dif-
fusion (which is considered an indirect indication of cellularity)
may reflect unfavourable tumour and host environment character-
istics (i.e. aggressive heterogenous tumour combined with less
pronounced immune response, immune cell influx etc) leading to
resistance to treatment. A study of patients with head and neck
squamous cell carcinoma, found that high ADC histogram range
measures (ADCdiff), reflecting more tumor heterogeneity on DWI,
was associated with poorer outcomes which is consistent with
our study [31]. In addition, in another study of advanced squamous
cell carcinoma of the head and neck, higher imaging uniformity
was predictive of local failure [32] which is consistent with the
T2w feature analysis in our study.
Our study has several limitations. Firstly, this is an exploratory
analysis and the results, whilst interesting and consistent with pre-
vious reports in squamous cell cancers, will require validation in a
larger cohort. Due to the large number of imaging features and
small number of patients with this rare cancer coupled with rela-
tively small number of events the risk of model overfitting is high
although we have made every effort to correct for this using two
K. Owczarczyk et al. / Radiotherapy and Oncology 134 (2019) 119–126 125separate indices (C-statistic as well as NRI) as well as internal
cross-validation analysis.
Secondly, we included both, local as well as metastatic/ com-
bined recurrence, as the primary outcome. Due to the limited num-
ber of events in our cohort we could not carry out separate logistic
regression analyses for these outcomes. Further studies are
required to find factors specifically associated with local or distant
tumour progression as this may carry therapeutic implication.
Thirdly, signal intensity variability from the MR acquisition pro-
tocols and reconstruction algorithms were inevitable due to intrin-
sic differences in the 1.5 T systems used. However, sequences were
the same type and standard quality assurance was performed. In
addition, first-order heterogeneity features, which have been
found to be most predictive in our study, have been shown in other
trials to be more reproducible [23] and less reliant on acquisition
parameters [33] than higher order texture features.
Furthermore, there were challenges in defining the optimal VOI
on the post CRT scans given the overlap between post CRT change
and residual tumor, if present. This was minimized by using a radi-
ation oncologist and radiologist in consensus as well as by inclusion
of functional sequenceswhichhave, in our previous publishedwork,
beendemonstrated to improveoutlining confidence [34]. Finally,we
were unable to independently validate our findings, however, going
forwardprospective investigation ofmodel performance in themul-
ticenter PLATO trial (ISRCTN 88455282) is planned.Conflict of interest statements
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